Predictive Oncology Inc. to Attend BIO DIGITAL, the World's Largest Biotech Partnering ExperienceGlobeNewsWire • 06/02/21
Predictive Oncology Inc.'s Wholly Owned Subsidiary, TumorGenesis, Partners with Cellevate ABGlobeNewsWire • 05/20/21
Predictive Oncology Reports Financial Results for Quarter Ended March 31, 2021 and Provides Business UpdateGlobeNewsWire • 05/12/21
Predictive Oncology Reports Year End 2020 Financial Results, Provides Business UpdateGlobeNewsWire • 03/15/21
POAI ‘s Helomics Division Announces Progress on Milestones for its AI-Driven Model of Ovarian CancerGlobeNewsWire • 02/24/21
Predictive Oncology Announces Closing of $17.6 Million Private Placement Priced At-the-MarketGlobeNewsWire • 02/23/21
Two Top Researchers find Breakthrough Discoveries using Predictive Oncology's Wholly Owned Subsidiary, TumorGenesis's TechnologyGlobeNewsWire • 02/17/21
Predictive Oncology Announces Closing of $7.4 Million Registered Direct Offering Priced At-the-Market under Nasdaq RulesGlobeNewsWire • 02/16/21
Predictive Oncology Announces $7.4 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesGlobeNewsWire • 02/11/21
Predictive Oncology's Wholly Owned Subsidiary Helomics announces the start of its drug repurposing project using its ground-breaking PeDAL™ platform for ovarian cancerGlobeNewsWire • 02/08/21
Predictive Oncology Has Regained Compliance with Nasdaq's Minimum Bid Price RequirementGlobeNewsWire • 02/02/21
Predictive Oncology Announces Closing of $4.1 Million Registered Direct Offering Priced At-the-Market under Nasdaq RulesGlobeNewsWire • 01/27/21
Predictive Oncology Announces $4.1 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesGlobeNewsWire • 01/22/21
Predictive Oncology Announces Closing of $2.2 Million Registered Direct Offering Priced At-the-Market under Nasdaq RulesGlobeNewsWire • 01/21/21
Predictive Oncology Reports That Its Wholly Owned Subsidiary, TumorGenesis, Has Sold Media to Two Top Research Medical CentersGlobeNewsWire • 01/14/21
Predictive Oncology Announces Closing of $3.074 Million Registered Direct Offering Priced At-the-Market under Nasdaq RulesGlobeNewsWire • 01/12/21
Predictive Oncology Announces $3,074,007 Registered Direct Offering Priced At-The-Market under Nasdaq RulesGlobeNewsWire • 01/08/21
Predictive Oncology's Wholly Owned Subsidiary Helomics completes integration of Quantitative MedicineGlobeNewsWire • 01/06/21
Predictive Oncology Announces Cancellation of Special Meeting in December 2020GlobeNewsWire • 12/29/20
Predictive Oncology Sends Letter to Shareholders Regarding Special Meeting to be Reconvened on December 30, 2020GlobeNewsWire • 12/09/20